世界の脳腫瘍の診断と治療市場の規模、シェア、傾向分析レポート – 業界の概要と2031年までの予測

脳腫瘍の診断と治療市場分析

脳腫瘍の診断と治療市場は、バイオテクノロジーと分子研究の進歩に牽引されて、大幅な成長を遂げています。この分野の発展には、細胞成分の効率と保存性を高める革新的な細胞溶解技術の導入が含まれます。企業は現在、さまざまな研究ワークフローにシームレスに統合できる、より洗練された自動化システムの開発に注力しています。たとえば、マイクロ流体デバイスと音響溶解システムの導入により、研究者が細胞サンプルを取り扱い、処理する方法に革命が起こり、溶解プロセスを正確に制御し、サンプルの損失を最小限に抑えることができます。さらに、試薬配合の進歩と新しい消耗品の開発により、脳腫瘍の診断と治療技術の汎用性と有効性が向上しています。市場はまた、製薬会社とバイオテクノロジー会社による研究開発への投資の増加、および個別化医療と再生療法への重点の高まりからも恩恵を受けています。

脳腫瘍の診断と治療の市場規模

世界の脳腫瘍の診断と治療の市場規模は、2023年に6億1,828万米ドルと評価され、2024年から2031年の予測期間中に7.82%のCAGRで成長し、2031年までに11億2,923万米ドルに達すると予測されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Researchがまとめた市場レポートには、詳細な専門家の分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みも含まれています。

脳腫瘍の診断と治療の市場動向

「酵素細胞分離法の採用増加」

脳腫瘍の診断と治療市場は、画像技術と個別化医療の進歩により成長しています。市場の主な傾向は、早期かつ非侵襲的な診断のための液体生検技術の採用が増えていることです。血流中の循環腫瘍 DNA (ctDNA) を分​​析する液体生検は、従来の組織生検よりも侵襲性の低い代替手段を提供します。たとえば、Biocept などの企業は、脳腫瘍のバイオマーカーを検出する液体生検プラットフォームを開発しており、これにより早期診断と治療計画の改善が可能になります。このような技術は、腫瘍の進行と治療への反応をリアルタイムで監視するのに特に役立ちます。さらに、免疫療法や精密放射線などの標的療法の進歩により、副作用が少なく、より効果的な治療オプションが提供されています。これらのイノベーションは、脳腫瘍の発生率の上昇と低侵襲性の診断ツールの需要と相まって、脳腫瘍の診断と治療市場の成長を牽引し、患者の転帰を改善し、市場の潜在性を高めています。

レポートの範囲と脳腫瘍の診断と治療市場のセグメンテーション

脳腫瘍の診断と治療市場の定義

脳腫瘍の診断と治療とは、脳内の細胞の異常な増殖を特定し、管理するために使用される医療プロセスを指します。診断には通常、腫瘍を検出するための MRI (磁気共鳴画像) や CT (コンピューター断層撮影) スキャンなどの画像技術と、腫瘍のサンプルを検査する生検などの技術が含まれます。液体生検や分子診断などの新しい方法も、非侵襲的な検出に使用されています。治療には、手術、放射線療法、化学療法、標的療法、免疫療法など、腫瘍の種類、場所、および段階に応じてさまざまなアプローチが含まれます。目標は、健康な脳組織への損傷を最小限に抑え、神経機能を維持しながら、腫瘍を除去または縮小することです。

脳腫瘍の診断と治療市場の動向

ドライバー

• 脳腫瘍の発生率上昇

脳腫瘍の発生率の上昇は、脳腫瘍の診断および治療市場を大きく牽引しています。世界のがん負担とがん対策戦略（GLOBOCAN）2020レポートによると、2020年には世界で1,930万人が新たにがんに罹患し、約1,000万人ががんで亡くなりました。罹患率の増加は、放射線や化学汚染物質への環境曝露、遺伝的素因などの要因の影響を受けています。脳腫瘍の症例が増加し続けるにつれて、高解像度の画像診断や分子診断などの高度な診断ツールの需要が高まり、標的療法や免疫療​​法などの革新的な治療オプションのニーズが高まっています。発生率の急増は、最先端のソリューションの継続的な開発と採用の必要性を直接的に刺激し、脳腫瘍の診断および治療市場の成長を促進します。

• 認知度の向上とスクリーニングプログラム

Growing awareness and screening programs are significantly impacting the early detection and diagnosis of brain tumors, leading to increased demand for diagnostic and therapeutic solutions. Public health initiatives and educational campaigns are playing a crucial role in this shift. For instance, organizations such as the American Brain Tumor Association (ABTA) run awareness campaigns that educate public about brain tumor symptoms and the importance of early screening. Such efforts have been linked to increased participation in screening programs, such as MRI scans for individuals at higher risk or those experiencing symptoms. "Brain Tumor Awareness Month" campaign, which raises awareness about the signs of brain tumors and encourages timely medical consultation is further disseminating the awareness and screening programs. As more people become aware of the importance of early detection and seek out screening services, the demand for advanced diagnostic tools and effective treatment options rises, further propelling growth in the brain tumor diagnosis and treatment market.

Opportunities

• Advancements in Imaging Technologies

Advancements in imaging technologies are significantly enhancing the accuracy and effectiveness of brain tumor diagnosis. For instance, the development of advanced MRI techniques, such as high-field MRI and functional MRI (fMRI), offers detailed insights into brain activity and tumor morphology, improving tumor localization and characterization. Additionally, molecular imaging technologies, including positron emission tomography (PET) with radiolabeled tracers, provide valuable information on metabolic activity and tumor cell proliferation, which is crucial for assessing tumor behavior and response to treatment. Specifically, 18F-FDG PET scans have demonstrated the ability to accurately differentiate between tumor types and evaluate treatment efficacy in brain tumor patients. Such innovations not only enhance diagnostic precision but also create opportunities for companies to develop and market cutting-edge imaging solutions, meeting the growing demand for advanced diagnostic tools in the brain tumor market.

• Expansion of Targeted Therapies and Immunotherapies

The expansion of targeted therapies and immunotherapies is transforming the treatment landscape for brain tumors, providing new avenues for combating these challenging conditions. Targeted therapies focus on specific genetic mutations that drive tumor growth, offering a more tailored approach to treatment. For instance, temozolomide is a chemotherapy drug designed to target the DNA repair mechanisms unique to certain brain tumors, such as glioblastomas. Immunotherapies, such as CAR-T cell therapy, where T cells are engineered to recognize and attack tumor cells, showing potential in treating brain tumors such as glioblastoma by targeting cancer cells while minimizing damage to healthy tissue. Companies that invest in these advanced treatment options can capitalize on these innovations, meeting the rising demand for effective brain tumor therapies and improving patient outcomes. Consequently creating great opportunities in the market growth.

Restraints/Challenges

• Complexity of Brain Tumors

The complexity of brain tumors presents a significant challenge in both diagnosis and treatment, as these tumors exhibit considerable variability in their types, locations, and genetic profiles. For instance, glioblastomas, a highly aggressive type of brain tumor, differ markedly from meningiomas, which generally have a better prognosis and less aggressive behavior. Glioblastomas often have diverse genetic mutations and varying responses to treatment, necessitating highly specialized diagnostic tools such as advanced MRI imaging and genetic profiling to accurately identify and understand the tumor's characteristics. Similarly, treatment plans must be tailored to each tumor's specific genetic and molecular features, requiring a multidisciplinary approach involving neurosurgeons, oncologists, and radiologists. This complexity not only complicates the development of standardized treatment protocols but also makes it challenging to implement personalized therapies consistently. Consequently hampering the brain tumor diagnosis and treatment market.

• Limited Availability of Advanced Diagnostic and Treatment Technologies

The limited availability of advanced diagnostic and treatment technologies significantly impacts the quality of care in the brain tumor market, creating disparities between well-equipped centers and those with fewer resources. For instance, cutting-edge imaging systems such as high-field MRI scanners and PET-CT systems, which are crucial for accurate tumor localization and monitoring, are often found only in specialized centers or high-income countries. Patients in lower-income regions or less developed healthcare settings may not have access to these technologies, leading to delays in accurate diagnosis and suboptimal treatment planning. Such disparity is exemplified by the availability of novel therapeutic agents, such as targeted therapies or immunotherapies, which may only be accessible through clinical trials or in countries with advanced healthcare infrastructure.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Brain Tumor Diagnosis And Treatment Market Scope

The market is segmented on the basis of product type, product analysis, diagnosis type, treatment type, and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Primary Brain Tumor
  • Meningioma
  • Gliomas
  • Astrocytomas
  • Pituitary Tumors
  • Others
• Secondary Brain Tumor

Product Analysis

• Stains and Varnishes
• Shellacs
• Lacquers
• Others

Diagnosis Type

• CT Scan
• MRI
• PET-CT Scan
• Molecular Testing
• EEG
• Others

Treatment Type

• Surgery
• Radiation Therapy
• Targeted Therapy
• Chemotherapy
• Immunotherapy

End User

• Hospitals
• Ambulatory Surgical Centers

Brain Tumor Diagnosis And Treatment Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product type, product analysis, diagnosis type, treatment type, and end-user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the brain tumor diagnosis and treatment market, primarily due to significant research and development efforts, a high incidence of brain tumor diagnoses, and increasing awareness of treatment and management options. The region's advanced healthcare infrastructure, coupled with substantial investments in oncology research, further strengthens its dominance in this market. Additionally, growing public awareness about early diagnosis and available treatment methods contributes to the rising demand for advanced brain tumor therapies in North America.

Europe is projected to witness the highest growth rate in the brain tumor diagnosis and treatment market during the forecast period of 2024 to 2031. This growth is largely driven by government initiatives aimed at raising awareness of advanced medical technologies and improving access to cutting-edge treatments across the region. Additionally, increased investment in healthcare infrastructure and research, along with growing public awareness about early diagnosis and advanced therapies, is expected to fuel the market's expansion in Europe.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Brain Tumor Diagnosis and Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Brain Tumor Diagnosis and Treatment Market Leaders Operating in the Market Are:

• ファイザー社（米国）
• メイヨー医学教育研究財団 (MFMER) (米国)
• GEヘルスケア（米国）
• アストラゼネカ（英国）
• メルク社（米国）
• シーメンス ヘルシナーズ AG (ドイツ)
• ケアストリームヘルス（米国）
• 日立製作所（日本）
• Koninklijke Philips NV (オランダ)
• 島津製作所（日本）
• キヤノンメディカルシステムズ（日本）
• エーザイ株式会社（日本）
• エレクタ（スウェーデン）
• バリアンメディカルシステムズ社（米国）
• 富士フイルム株式会社（日本）
• ナントミクス（米国）
• ホロジック社（米国）
• サーモフィッシャーサイエンティフィック株式会社（米国）
• ジェネンテック社（米国）
• ブリストル・マイヤーズ スクイブ社（米国）

脳腫瘍の診断と治療市場の最新動向

• 2024年3月、アストラゼネカはがん治療の進歩を加速させることを目指してフュージョン・ファーマシューティカルズの買収を完了した。この買収は、化学療法や放射線療法などの従来の治療法から、患者の転帰を向上させるより革新的で的を絞ったアプローチへの移行に焦点を当てている。
• 2024年1月、GEヘルスケアはAI駆動型イメージングおよびワークフローソリューションを専門とするMIMソフトウェアを買収しました。この買収により、GEヘルスケアはMIMの高度なAI対応ツールを腫瘍学や神経学などの分野に統合し、これらの重要なヘルスケア領域全体で診断精度を高め、治療計画を改善できるようになります。

SKU-60266